aibio
Listings ·
Alterity reports A$37.3 million cash after 1-for-50 share consolidation
The quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives.
ATH Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) news
Latest Alterity Therapeutics news
- Financings
Alterity reports A$54.56M cash after A$20M placement in the quarter
Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds.
What Alterity Therapeutics does
Alterity Therapeutics Ltd. is an Australian company, incorporated on November 11, 1997, that develops first-in-class therapies for neurodegenerative diseases. Its technology centers on compounds that redistribute excess labile iron in the central nervous system, and on platform compounds that target the interaction of metals and proteins implicated in disease. Its lead drug candidate, ATH434, is an oral iron chaperone that has been shown in preclinical animal studies to reduce the accumulation and aggregation of alpha-synuclein. Its clinical development program is focused on multiple system atrophy (MSA), a rare Parkinsonian disorder with no approved treatments. The company has also conducted a Natural History Study in MSA and has a preclinical program in Parkinson's disease. Its chemical library includes more than 1000 novel compounds. The company also describes next generation zinc ionophores, invented in 2021, that may modulate zinc for diseases such as cancer, neurological diseases and infectious diseases. Its chemistry program is undertaken within laboratories leased from The University of Melbourne's Bio21 Molecular Science and Biotechnology Institute.
| Product or program | What it is | Stage |
|---|---|---|
| ATH434 | Oral iron chaperone for MSA and Parkinson's disease | clinical development in MSA |
| Parkinson's disease program | Iron chaperone compounds for Parkinson's disease and related disorders | preclinical |
Questions about Alterity Therapeutics
What is the ticker symbol of Alterity Therapeutics?
Alterity Therapeutics Ltd. trades under the ticker ATH on ASX.
Where is Alterity Therapeutics listed?
Alterity Therapeutics Ltd. is listed on ASX. Our directory also records these other listings: LS:A2PHDZ; NASDAQ:ATHE; OTC:PRNAF.
What is the SEC CIK of Alterity Therapeutics?
The SEC Central Index Key (CIK) for Alterity Therapeutics Ltd. is 1131343. Its filings are on SEC EDGAR.
How many shares does Alterity Therapeutics have outstanding?
217,508,862 shares as of 2026-06-30, per the cover page of its 20-F filed 2026-08-28.
Which country or territory is Alterity Therapeutics listed under?
Our directory records Alterity Therapeutics Ltd. under Australia.
What does Alterity Therapeutics do?
Our directory classifies Alterity Therapeutics Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Alterity Therapeutics?
The ISIN recorded for Alterity Therapeutics Ltd. is AU0000043945.
Does aibio.space cover Alterity Therapeutics?
aibio.space lists Alterity Therapeutics Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Alterity Therapeutics incorporated?
SEC records list its state or country of incorporation as C3.
What does Alterity Therapeutics develop?
Alterity Therapeutics Ltd. is an Australian company, incorporated on November 11, 1997, that develops first-in-class therapies for neurodegenerative diseases. Its technology centers on compounds that redistribute excess labile iron in the central nervous system, and on platform compounds that target the interaction of metals and proteins implicated in disease.
What is ATH434 from Alterity Therapeutics?
ATH434: Oral iron chaperone for MSA and Parkinson's disease Stage: clinical development in MSA.
What is Parkinson's disease program from Alterity Therapeutics?
Parkinson's disease program: Iron chaperone compounds for Parkinson's disease and related disorders Stage: preclinical.
What is the latest Alterity Therapeutics (ATH) stock news?
Our latest story on Alterity Therapeutics, dated Jul 30, 2026: "Alterity reports A$37.3 million cash after 1-for-50 share consolidation". The quarterly cash flow report also shows an A$3,982,992 tax incentive refund and says the company is evaluating strategic and funding alternatives. Source.
What is Alterity Therapeutics's latest stock offering or financing news?
Our latest financing story, dated Oct 31, 2025: "Alterity reports A$54.56M cash after A$20M placement in the quarter". Operating cash outflows were A$5.34M for the quarter ended 30 September 2025. The company says the placement was led by healthcare-focused funds. Source.
How long will Alterity Therapeutics's cash last?
From our story of Jul 30, 2026: The company marked its three going-concern questions as N/A. The form requires those answers only where the estimated funding is less than two quarters. Source.
Investor discussion: Alterity Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
Stock chart
SEC filings and registration
- SEC name
- Alterity Therapeutics Ltd
- CIK
- 1131343
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- ATHE (Nasdaq), PRNAF (OTC)
- State or country of incorporation
- C3
- Fiscal year ends
- June 30
- Filer category
- Non-accelerated filer
- Business address
- LEVEL 15, 500 COLLINS STREET, MELBOURNE, VIC 3000
- Phone
- 61 3 9349 4906
- Shares outstanding
- 217,508,862 as of 2026-06-30 (20-F filed 2026-08-28)
- Former names
- PRANA BIOTECHNOLOGY LTD
Recent filings
Listing details
- Company
- Alterity Therapeutics Ltd.
- Ticker
- ATH
- Listing
- ASX
- Country or territory
- Australia
- Business scope
- Pharmaceuticals: Major
- ISIN
- AU0000043945
- Other listed symbols
- LS:A2PHDZ; NASDAQ:ATHE; OTC:PRNAF
- Last quote in directory
- 2026-10-22
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction